Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) CEO Christopher von Jako speaks to Thomas Warner from Proactive after the medical imaging technology company announced that NUKEM Isotopes GmbH recently increased its stake in Polarean to over 10%, marking a shift in the company's shareholder dynamics.
Von Jako explains that NUKEM, a key player in the trading of stable isotopes used in various industries including medical imaging, has been a long-term partner of Polarean. They supply xenon-129 gas, a critical component of Polarean's functional MRI product.
Von Jako frames it as a strong vote of confidence in Polarean's technology and future, describing it as a "clear indication of interest and belief in the company and the technology." Currently, von Jako is focusing on attending the annual 129Xe MRI Clinical Trials Consortium in Florida, a significant event for discussing scientific and clinical applications of their technology.
He goes on to say that Polarean's primary goals for 2024 include driving utilisation, expanding their user base, improving reimbursement structures, and pursuing further label expansion.
The relationship with NUKEM is seen as a cornerstone in these efforts, as Polarean looks forward to a promising year ahead.
